Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Kína2. fázis

An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia

A legfontosabb adatok

Ki végzi
Institute of Hematology & Blood Diseases Hospital, China
Hol
Tianjin (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
20 fő, tervezett
Kezdés
2025. márc. 3.
Várható befejezés
2027. jan. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • CM336 Injection
A regiszteradat frissítve
2025. március 13.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with primary immune thrombocytopenia (ITP), a low platelet count caused by the immune system, that did not respond to earlier treatments. They will get CM336.

Életkor
18 years and older.
Nem
Men and women can join.
A betegség stádiuma
Persistent or chronic primary ITP that has not responded to treatment. Daily activity score (ECOG) of 2 or less.
Korábbi kezelés
Steroid (glucocorticoid) treatment must have failed. People must also have had no response to at least one thrombopoietin receptor agonist and no lasting response to anti-CD20 (e.g., rituximab) or anti-CD38 antibody, or no response or relapse after spleen removal. Maintenance treatment (prednisone up to 20mg, TPO receptor agonists) must be at a stable dose for at least 4 weeks before the first dose. People who had any anti-BCMA antibody drug cannot join.
Biomarker vagy leletérték
Platelet count below 30×109/L within 48 hours before the first dose.

A részvétel fő kizáró okai

  • Autoimmune hemolytic anemia, or secondary or inherited low platelet count.
  • Blood clot in the past 12 months, or severe bleeding such as bleeding in the brain or stomach.
  • Past stem cell transplant from a donor or organ transplant.
  • Cancer within 5 years, HIV or syphilis antibody positive, or uncontrolled infection such as hepatitis B or C.
  • Pregnant or breastfeeding.

A regiszter feltételei, szó szerint

Mind a 28 feltétel megnézéseKevesebb

Ki vehet részt

  • Age 18 and above, male or female
  • Conform to the diagnostic criteria of persistent or chronic immune thrombocytopenia (ITP)
  • Failure of previous glucocorticoid therapy
  • In the second-line treatment phase, eligible subjects must meet any of the following criteria: (1) Demonstrate no response to treatment with at least one thrombopoietin receptor agonist (including but not limited to recombinant human thrombopoietin [rhTPO], eltrombopag, hetrombopag, avatrombopag, or romiplostim); Fail to achieve sustained response (manifested as non-response, loss of response, or disease relapse) following anti-CD20 monoclonal antibody therapy (e.g., rituximab) or anti-CD38 monoclonal antibody therapy; (2) Exhibit no therapeutic response or experience disease relapse after splenectomy
  • The platelet count was <30×109/L within 48 hours before the first administration
  • ECOG physical state score ≤ 2 points
  • Patients receiving maintenance treatment (including corticosteroids (less than or equal to 20mg prednisone), TPO receptor agonists, etc.) must have a stable dose at least 4 weeks before the first administration
  • Signed and dated written informed consent

Ki nem vehet részt

  • Received any treatment of anti-BCMA antibody drug
  • History of any thrombotic or embolic events in the 12 months prior to the first dose or accompanied by extensive and severe bleeding, such as hemoptysis, upper gastrointestinal hemorrhage, intracranial hemorrhage, etc
  • Participated in any other study drug or exposure to other study drugs within 4 weeks or 5 half-lives before the first dose (whichever is longer)
  • Use of anticoagulants or any drug with antiplatelet effects (such as aspirin) within 3 weeks before the first dose
  • Splenectomy was performed within 6 months before the first dose
  • Patients who received azathioprine, danazol, cyclosporine A, tacrolimus, sirolimus, etc., within 4 weeks prior to the first dose; or received treatments such as CD20 monoclonal antibodies (e.g., rituximab), CD38 monoclonal antibodies, cyclophosphamide, or vindesine within 3 months prior to the first dose;
  • Received a live vaccine within 4 weeks before the first dose, or planned to receive any live vaccine during the clinical trial
  • Those who have received allogeneic stem cell transplantation or organ transplantation in the past
  • Accompanied by autoimmune hemolytic anemia, or various secondary and hereditary thrombocytopenia
  • Other serious diseases that may limit the subject's participation in this trial (such as diabetes; Hepatic and renal insufficiency; Severe cardiac insufficiency; Myocardial obstruction or unstable arrhythmia or unstable angina pectoris in recent 6 months; Gastric ulcer, etc.)
  • Patients with malignant tumors within 5 years before the screening
  • A history of severe recurrent or chronic infection
  • A known or suspected history of immunosuppression, including a history of invasive opportunistic infections
  • HIV antibody or syphilis antibody positive
  • Accompanied by uncontrollable active infection, including hepatitis B, hepatitis C; Pregnant women, suspected pregnancies (positive pregnancy test for human chorionic gonadotropin in urine at screening) and lactating patients
  • Patients with mental disorders who cannot normally obtain informed consent and conduct trials and follow-up
  • Treatment with ITP (methylprednisolone, platelet, gamma-globulin infusion or TPO receptor agonist therapy) within 2 weeks before the first dose
  • Clinically significant laboratory abnormalities at the time of screening
  • Patients whose symptoms of toxicity from pre-trial treatment have not resolved
  • Any other ineligibility for subjects in the study was assessed by the investigator

Helyszínek itt: Kína

  • Chinese Academy of Medical Science and Blood Disease HospitalTianjin, KínaContact: Yunfei Chen, MDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

To evaluate the efficacy and safety of CM336 in the treatment of refractory adult primary immune thrombocytopenia

A vizsgálat csoportja

  • Intervention(CM336)A vizsgált kezelés

    CM336 (Anticipated enrollment of 20 to 30 subjects)

    Kezelés: CM336 Injection

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
An Open, Exploratory Clinical Study to Assess Safety and Efficacy of BCMA-CD3 Bispecific Antibody CM336 in the Treatment of Primary Immune Thrombocytopenia
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2025. március 13.